Supplemental New Drug Application for ACEON(R) Label Expansion Based on EUROPA Outcomes Data Submitted to U.S. FDA
December 13 2004 - 5:55PM
PR Newswire (US)
Supplemental New Drug Application for ACEON(R) Label Expansion
Based on EUROPA Outcomes Data Submitted to U.S. FDA MARIETTA, Ga.
and PALO ALTO, Calif., Dec. 13 /PRNewswire-FirstCall/ -- Solvay
Pharmaceuticals, Inc. and CV Therapeutics, Inc. (NASDAQ:CVTX)
announced today that Solvay Pharmaceuticals has submitted a
supplemental new drug application for ACEON(R) (perindopril
erbumine) Tablets to the U.S. Food and Drug Administration (FDA)
seeking an expansion to the label. The proposed label expansion is
based on the EUROPA (EUropean trial on Reduction Of cardiac events
with Perindopril in patients with stable coronary Artery disease)
study which assessed the ability of perindopril to reduce
cardiovascular mortality, nonfatal myocardial infarction and
resuscitated cardiac arrest in a broad population of patients with
stable coronary artery disease, but without heart failure. The
companies recently entered into a co-promotion agreement for
ACEON(R), an angiotensin converting enzyme (ACE) inhibitor with
tissue activity approved in the United States for the treatment of
patients with essential hypertension. About the EUROPA Study EUROPA
was a multicenter, randomized, double-blind, placebo-controlled
trial in 12,218 patients with stable coronary disease and without
heart failure for at least three years. The study was designed to
assess the ability of perindopril to reduce cardiovascular death,
myocardial infarction and resuscitated cardiac arrest. The results
from EUROPA were published in The Lancet on September 6, 2003. In
Europe, perindopril is marketed under the brand name Coversyl(R).
Perindopril is one of the leading ACE inhibitors in Europe. About
ACE Inhibitors ACE inhibitors act to reduce hypertension by
interfering with the conversion of angiotensin I to
artery-constricting, angiotensin II. Blocking the production of
angiotensin II results in arterial vasodilation and an accompanying
reduction in blood pressure. ACE inhibitors currently are
recommended as first-line therapy for hypertension in certain
patient populations, because of their safety and efficacy. Most
recently, the Seventh Report of the Joint National Committee on
Prevention, Detection, Evaluation and Treatment of High Blood
Pressure has recommended ACE inhibitors as one of the initial
therapy choices for compelling indications such as heart failure,
postmyocardial infarction, high coronary disease risk, diabetes,
chronic kidney disease and recurrent stroke prevention. ACEON(R) is
only indicated for the treatment of patients with essential
hypertension. Certain ACE inhibitors, including ACEON(R), which
have been shown to have an enhanced affinity for the tissues, are
known as tissue-ACEs. About ACEON(R) ACEON(R) is an ACE inhibitor
indicated for the treatment of essential hypertension. It offers
continuous 24-hour blood pressure control with once-daily dosing
for hypertensive patients. ACEON(R) may be used alone or with other
classes of antihypertensives. ACEON(R) is contraindicated in
patients known to be hypersensitive to this product or to any other
ACE inhibitors and in patients with a history of angioedema related
to previous treatment with an ACE inhibitor. When used in pregnancy
during the second and third trimesters, ACE inhibitors can cause
injury and even death to the developing fetus. When pregnancy is
detected, ACEON(R) should be discontinued as soon as possible.
About CV Therapeutics CV Therapeutics, Inc., headquartered in Palo
Alto, California, is a biopharmaceutical company focused on
applying molecular cardiology to the discovery, development and
commercialization of novel, small molecule drugs for the treatment
of cardiovascular diseases. CV Therapeutics has entered into an
agreement with Solvay Pharmaceuticals to co-promote ACEON(R)
(perindopril erbumine) for the treatment of hypertension, and CV
Therapeutics currently has four clinical development drug
candidates. CV Therapeutics has received an approvable letter from
the FDA relating to its new drug application for
Ranexa(TM)(ranolazine) for the potential treatment of chronic
angina, and has submitted an application for the approval of
ranolazine for the potential treatment of chronic angina to the
European Medicines Agency. Regadenoson is a selective A2A-adenosine
receptor agonist for potential use as a pharmacologic stress agent
in cardiac perfusion imaging studies. Tecadenoson is a selective
A1-adenosine receptor agonist for the potential reduction of rapid
heart rate during atrial arrhythmias. Adentri(TM) is a selective
A1-adenosine receptor antagonist for the potential treatment of
heart failure and has been licensed to Biogen Idec Inc. For more
information, please visit CV Therapeutics' website at
http://www.cvt.com/. Ranexa, regadenoson, tecadenoson and Adentri
have not been approved for marketing by the FDA or any foreign
regulatory authorities. These products are currently under
investigation in clinical trials subject to United States
Investigational New Drug applications, and as applicable,
appropriate clinical trial applications to regulatory authorities
outside the United States. About Solvay Pharmaceuticals, Inc.
Solvay Pharmaceuticals, Inc.
(http://www.solvaypharmaceuticals-us.com/) of Marietta, Georgia
(USA), is a research-driven pharmaceutical company that seeks to
fulfill unmet medical needs in the therapeutic areas of cardiology,
gastroenterology, mental health, women's health and a select group
of specialized markets including men's health. It is a part of the
global Solvay Pharmaceuticals organization whose core activities
consist of discovering, developing and manufacturing medicines for
human use. Solvay Pharmaceuticals is a subsidiary corporation of
the worldwide Solvay Group of chemical and pharmaceutical companies
headquartered in Brussels, Belgium. Except for the historical
information contained herein, the matters set forth in this press
release, including statements as to development, clinical studies,
regulatory review, and commercialization of products, are
forward-looking statements within the meaning of the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially,
including, early stage of development; regulatory review and
approval of our products; the conduct and timing of clinical
trials; the dependence on collaborative and licensing agreements;
commercialization of products; and other risks detailed from time
to time in CVT's SEC reports, including its most recent Annual
Report on Form 10-K, and its most recent Quarterly Report on Form
10-Q. CVT disclaims any intent or obligation to update these
forward-looking statements. DATASOURCE: CV Therapeutics, Inc.
CONTACT: investors, Christopher Chai, Treasurer & Executive
Director, Investor Relations, +1-650-384-8560, or media, John
Bluth, Senior Director, Corporate Communications, +1-650-384-8850,
both for CV Therapeutics, Inc.; or Gabrielle Braswell, Assistant
Director, Public Affairs, Solvay Pharmaceuticals, Inc.,
+1-770-578-5637 Web site: http:///
http://www.solvaypharmaceuticals-us.com/ Web site:
http://www.cvt.com/
Copyright
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jul 2023 to Jul 2024